Innovating Works

MERCK SHARP & DOHME CORP

Desconocido
PharmaLedger: PharmaLedger MERCK SHARP & DOHME CORP participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage The PharmaLedger project will create a blockchain-based framework for the efficient digitization of the healthcare industry. The goal of the...
2019-12-16 - 2022-12-31 | Financiado
NeuroDeRisk: Neurotoxicity De Risking in Preclinical Drug Discovery MERCK SHARP & DOHME CORP participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage The adverse effects of pharmaceuticals on the central or peripheral nervous systems are poorly predicted by the current in vitro and in vivo...
2019-03-15 - 2022-09-30 | Financiado
VITAL: Vaccines and Infectious Diseases in the Ageing PopuLation MERCK SHARP & DOHME CORP participó en un H2020: H2020-JTI-IMI2-2017-12-two-stage Today’s major challenge is to improve efficacy of vaccines to protect the growing ageing population against infectious diseases (ID). The VI...
2018-12-10 - 2024-12-31 | Financiado
PARADIGM: Patients Active in Research and Dialogues for an Improved Generation of Medicines Advancing meaning... MERCK SHARP & DOHME CORP participó en un H2020: H2020-JTI-IMI2-2016-10-two-stage PARADIGM will provide a unique framework that enables structured, effective, meaningful, ethical, innovative, and sustainable patient engage...
2018-06-04 - 2020-11-30 | Financiado
VSV-EBOPLUS: SYSTEMS ANALYSIS OF ADULT AND PEDIATRIC RESPONSES TO THE VSV ZEBOV EBOLA VACCINE Sofia ref. 11606... MERCK SHARP & DOHME CORP participó en un H2020: H2020-JTI-IMI2-2015-08-single-stage The vesicular stomatitis virus (VSV)-Zaire Ebola vaccine (VSV-ZEBOV) is a recombinant vector-based vaccine in which the VSV envelope glycopr...
2017-06-12 - 2023-03-31 | Financiado
IB4SD-TRISTAN: Imaging Biomarkers IBs for Safer Drugs Validation of Translational Imaging Methods in Drug Safety... MERCK SHARP & DOHME CORP participó en un H2020: H2020-JTI-IMI2-2015-07-two-stage 1.Our consortium has broad, deep experience of drug development and imaging biomarker (IB) validation. We are internationally recognized exp...
2017-03-10 - 2024-12-31 | Financiado
DO-IT: Big Data for Better Outcomes Policy Innovation and Healthcare System Transformation Sofia ref. 1... MERCK SHARP & DOHME CORP participó en un H2020: H2020-JTI-IMI2-2015-07-two-stage The overall goal of the Big Data for Better Outcomes (BD4BO) programme is to facilitate the use of ‘big data’ to promote the development of...
2017-01-30 - 2019-01-31 | Financiado
PREFER: Patient Preferences in benefit risk assessments during the drug life cycle Sofia ref. 115966 MERCK SHARP & DOHME CORP participó en un H2020: H2020-JTI-IMI2-2015-05-two-stage The PREFER project will deliver an overview and evaluation of preference elicitation methods to be applied in the entire drug life cycle, i....
2016-10-21 - 2022-05-31 | Financiado
DRIVE-AB: DRIVING RE INVESTMENT IN R D AND RESPONSIBLE ANTIBIOTIC USE MERCK SHARP & DOHME CORP participó en un FP7: Antimicrobial resistance (AMR) is widespread. Its global human and economic burden is tremendous and increasing annually. Yet today only a f...
Financiado
U-BIOPRED: Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes MERCK SHARP & DOHME CORP participó en un FP7: Rationale The inability of pre-clinical studies to predict clinical efficacy is a major bottleneck in drug development. In severe asthma thi...
Financiado
RAPP-ID: Development of RApid Point of Care test Platforms for Infectious Diseases MERCK SHARP & DOHME CORP participó en un FP7: RAPP-ID (Development of RApid Point-of-Care test Platforms for Infectious Diseases) will develop a Point-of-Care Test (POCT) for rapid (hosp...
Financiado
EPAD: European Prevention of Alzheimer s Dementia Consortium MERCK SHARP & DOHME CORP participó en un FP7: Background: The secondary prevention of Alzheimer’s dementia (AD) is achievable if we can identify individuals at risk of disease progressio...
Financiado
ADVANCE: Accelerated Development of Vaccine benefit risk Collaboration in Europe MERCK SHARP & DOHME CORP participó en un FP7: Aim: The ADVANCE vision is focused on Timely and Best Evidence on Vaccine Effects. Our mission is to establish a best practice framework to...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.